| Autor: |
Makashova ES; Burdenko Neurosurgical Center, Moscow, Russia.; Loginov Moscow Clinical Research Practical Center, Moscow, Russia., Zolotova SV; Burdenko Neurosurgical Center, Moscow, Russia., Absalyamova OV; Burdenko Neurosurgical Center, Moscow, Russia., Galkin MV; Burdenko Neurosurgical Center, Moscow, Russia., Petrokovskaya AV; Sechenov First Moscow State Medical University, Moscow, Russia., Kozlov AV; Burdenko Neurosurgical Center, Moscow, Russia., Golanov AV; Burdenko Neurosurgical Center, Moscow, Russia.; Russian Medical Academy of Continuous Professional Education, Moscow, Russia. |
| Abstrakt: |
Schwannomatoses is a new classification unit for all the hereditary diseases caused by chromosome 22 damage followed by multiple benign neoplasms of the peripheral and central nervous system. Schwannomatosis occurs as a result of damage to different genes: NF2, SMARCB1, LZRT1, loss of heterozygosity of the long arm of chromosome 22. Nevertheless, clinical manifestations are similar. Molecular diagnostics not only confirms the diagnosis, but also predicts the course of disease. Thus, the most severe clinical manifestations are observed in patients with violation of semantic sequences and reading frame shift in exons 2-13 of the NF2 gene. A more favorable course with less number of tumors is observed in patients with somatic mosaicism. Stereotactic irradiation and surgery are the main treatment options for schwannomatosis. However, there is evidence of effective targeted therapy with bevacizumab (inhibitor of vascular endothelial growth factor). Bevacizumab is used in patients with bilateral vestibular schwannomas and high risk of hearing loss, as well as for intramedullary tumor growth control. |
